ProCE Banner Series

PARP Inhibitor Combination Approaches in Prostate Cancer: Interpretation of Clinical Findings and Regulatory Approvals

Join us in San Francisco or online for a CME-certified satellite symposium featuring expert perspectives on integrating PARP inhibitor combinations into clinical practice for prostate cancer. Throughout the symposium, learners will have the opportunity to directly text questions to the panel. Register now!

  AMA
Who Should Attend

This educational program is intended for oncologists and other healthcare professionals who care for patients with prostate cancer.

All Events

PARP Inhibitor Combination Approaches in Prostate Cancer: Interpretation of Clinical Findings and Regulatory Approvals

Past Events

January

25

2024

6:30 PM - 8:00 PM Pacific Time (PT)

In-personVirtual

Marriott Marquis San Francisco, 780 Mission St, San Francisco, California 94103

Faculty

ProCE Banner Faculty
Neeraj Agarwal, MD

Professor of Medicine
Senior Director for Clinical Research, Huntsman Cancer Institute (HCI)
Presidential Endowed Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)
Salt Lake City, Utah

ProCE Banner Faculty
Andrew Armstrong, MD, ScM, FACP

Professor of Medicine, Surgery, Pharmacology and Cancer Biology
Director of Research
The Duke Cancer Institute Center for Prostate and Urologic Cancers
Divisions of Medical Oncology and Urology
Duke University
Durham, North Carolina

ProCE Banner Faculty
Tanya B. Dorff, MD

Professor of Medicine
Vice Chair for Clinical Affairs
Department of Medical Oncology
City of Hope National Medical Center
Duarte, California

Topics

Registration and Dinner: 6:00 PM - 6:30 PM PT

  • Welcome and Introduction
  • Single-Agent PARP Inhibitors in Prostate Cancer
    • Panel Discussion and Patient Cases
  • Understanding the Interdependencies of Targeted Pathways: Rationale for Combinations
    • Panel Discussion and Patient Cases
  • PARP Combinations in Prostate Cancer
    • Panel Discussion and Patient Cases
  • Closing Remarks, Panel Discussion, and Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Prostate Cancer

Target Audience
This educational program is intended for oncologists and other healthcare professionals who care for patients with prostate cancer. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate the medical need and rationale for PARP inhibitors and PARP inhibitor–based combinations in prostate cancer
  • Assess homologous recombination repair mutations and BRCA mutations to meet the currently approved use of PARP inhibitors for the treatment of prostate cancer
  • Plan PARP inhibitor–based combination therapy for patients with advanced prostate cancer, considering HRRm and BRCAm status, recent guideline updates, FDA approvals, and expert recommendations
  • Identify patients with prostate cancer eligible for enrollment on clinical trials investigating PARP inhibitor-based combinations

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck & Co., Inc., Rahway, NJ, USA.